Dai­ichi Sankyo launch­es glob­al R&D re­struc­tur­ing, look­ing to slash costs in an over­haul

You can add Japan’s Dai­ichi Sankyo to the list of phar­ma com­pa­nies re­struc­tur­ing their R&D or­ga­ni­za­tions.

Like Take­da be­fore it and a whole line­up of US and Eu­ro­pean phar­mas, Dai­ichi Sankyo is shut­ter­ing a re­search fa­cil­i­ty in In­dia and ax­ing 170 staffers. And the com­pa­ny says it is in the process of slash­ing costs around the world as it frees up cash.

In a state­ment, the com­pa­ny not­ed:

Dai­ichi Sankyo is re­view­ing its glob­al R&D sys­tem with the aim of de­creas­ing R&D op­er­a­tions costs and re­dis­trib­ut­ing re­sources to the fur­ther de­vel­op­ment of its R&D pipeline.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER